A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs PRX 002 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PASADENA
  • Sponsors Roche
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 19 Jun 2021 to 29 Jun 2021.
    • 11 Sep 2017 Planned End Date changed from 19 Oct 2020 to 19 Jun 2021.
    • 11 Sep 2017 Planned primary completion date changed from 29 Jul 2019 to 31 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top